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Angiotensin II (Ang II) is a main effector peptide in the renin–angiotensin system and participates in the regulation of vascular tone. It
also has a role in the expression of growth factors that induce neovascularisation which is closely associated to the growth of
malignant gliomas. We have shown that the selective blockage of the AT1 receptor of angiotensin inhibites tumour growth, cell
proliferation and angiogenesis of C6 rat glioma. The aim of this study was to study the effects of the blockage of AT1 receptor on the
synthesis of growth factors, and in the genesis of apoptosis in cultured C6 glioma cells and in rats with C6 glioma. Administration of
losartan at doses of 40 or 80mgkg
 1 to rats with C6 glioma significantly decreased tumoral volume and production of platelet-
derived growth factor, vascular endothelial growth factor and basic fibroblast growth factor. It also induced apoptosis in a dose-
dependent manner. Administration of Ang II increased cell proliferation of cultured C6 cells which decreased by the administration of
losartan. Our results suggest that the selective blockage of AT1 diminishes tumoral growth through inhibition of growth factors and
promotion of apoptosis.
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The renin angiotensin aldosterone system (RAAS) has an
important role in the regulation of blood pressure and fluid
electrolyte balance. Angiotensin II (Ang II), a major participant in
the RAAS, was initially described as a vasoconstrictor, but recent
studies have revealed that it also participates in cell growth, cell
differentiation and apoptosis (Stoll et al, 1995; Escobar et al, 2004),
and has a role in cell migration and conformation of the
extracellular matrix (Coker et al, 2001). Some reports indicate
that Ang II induce neovascularisation (Fernandez et al, 1985; Le
Noble et al, 1991; Andrade et al, 1996) due to stimulation of growth
factors, such as platelet-derived growth factor (PDGF) (Khachigian
et al, 2000; Cook et al, 2002), transforming growth factor beta b
(TGFb) (Kagami et al, 1994; Ohta et al, 1994; Hamaguchi et al,
1999; Weigert et al, 2002), insulin-like growth factor 1 (IGF-1)
(Brink et al, 1999; Haddad et al, 2003), basic fibroblast growth
factor (bFGF) (Peng et al, 2001), vascular endothelial growth factor
(VEGF) (Otani et al, 1998; Tamarat et al, 2002) and angiopoietin 2
(Otani et al, 2001). Angiotensin II also induces the expression of
proto-oncogenes in smooth vascular muscle cells, including c-fos,
c-jun, c-myc, erg-1, VL-30, and the activator of the protein 1
complex (Cook et al, 2002), Interestingly, many of these effects are
inhibited by the blockage of the AT1 receptor (Fujiyama et al,
2001). Angiotensin II has a dual and paradoxical intervention in
apoptosis through its receptors AT1 functioning as antiapoptotic
and AT2 functioning as proapoptotic (Stoll et al, 1995).
Experimentally, the RAAS has been associated to proliferation of
tumours; Ang II receptors have been found on the cell surface and
cytoplasm of human tumours such as breast cancer (Guerra et al,
1993; Inwang et al, 1997; Berry et al, 2000; Muscella et al, 2002),
hepatic carcinoma (Yoshiji et al, 2002), renal carcinoma (Hii et al,
1998; Miyajima et al, 2002), melanoma (Egami et al, 2003), colo-
rectal carcinoma, squamous cell carcinoma (Takeda and Kondo,
2001), pancreas cancer (Fujimoto et al, 2001) and sarcomas
(Volpert et al, 1996; Fujita et al, 2002).
Glioma is the most frequent primary tumour of the brain.
Malignant gliomas are still associated with poor prognosis, the
mean survival time of patients with glioblastoma multiforme
(GBM) is 1 year, and it has not changed significantly for the last
three decades (Lopez-Gonzalez and Sotelo, 2000). Glioblastoma
multiforme is accompanied by extensive angiogenesis which is
essential for tumoral growth and invasiveness; it also produces a
vast amount of growth factors such as PDGF, VEGF, HGF and FGF
(Strugar et al, 1995; Arrieta et al, 1998, 2002; Moriyama et al, 1999;
Schmidt et al, 1999). In brain parenchyma there is a local RAAS,
some neurons, glial cells and glioma cells express renin,
angiotensinogen and receptors for Ang II (AT1 and AT2) (Ganong,
1984, Ariza et al, 1988; Fogarty et al, 2002; Juillerat-Jeanneret et al,
2004). We have previously shown that the blockage of AT1
receptors in rats with C6 glioma inhibited tumour growth, cell
proliferation and angiogenesis (Rivera et al, 2001). The aim of this
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sstudy was to determine in vitro (in cultured C6 glioma cells) and
in vivo (in rats with C6 glioma) the effects of the blockage of the
AT1 receptor on the synthesis of growth factors and its relation
with cell proliferation and apoptosis.
MATERIALS AND METHODS
Glioma induction
C6 glioma cells (American Tissue Culture Collection Rockville,
MD, USA) were cultured under sterile conditions at 371Ci na
humid environment with 5% CO2 in Dulbecco’s modified Eagle’s
medium (DME) (Sigma chemical company, Saint Louis Missouri,
USA) supplemented with 10% foetal bovine serum (GIBCO, New
York, USA). After the cultures became confluent, the cells were
washed with saline solution and harvested; 10
7 C6 cells from this
source were inoculated intraperitoneally in a male Wistar rat; 2
weeks later, a large tumour was obtained (Guevara and Sotelo,
1999), it was mechanically dispersed in saline solution (1:1) at
41C, 10
7 cells from this source were subcutaneously injected in the
left thigh of 40-day-old Wistar rats (Arrieta et al, 2001). All animals
developed a noticeable tumour within 2 weeks. All animals used in
this study were handled in accordance to the guidelines of the
coordinating committee on cancer research for the welfare of
animals with experimental neoplasms.
Blockage of AT1 in vivo
When the tumour had reached a diameter of 1.5cm, the rats were
randomly assigned either to the control group (n¼40), to the
losartan 40mgKg
 1 group (L40) (n¼40), or to the losartan
80 mgKg
 1 group (L80) (n¼40). Losartan (Merck-Sharp & Dohme,
Mexico) was given orally, once a day, for 30 days. At the end of the
experiment, 20 rats from each group were anaesthetised and
perfused by intracardiac route with 10% formalin in saline solution
for histological study. Before perfusion, the animals were bled by
intracardiac puncture to analyse haematological and chemical
parameters in blood; the body weight of animals from all groups
remained similar throughout the study. The tumour was dissected
and its volume was determined by water displacement. The tumours
from nonperfused animals were kept at  701C until analysis.
Histological analysis and apoptosis in vivo
For microscopic study, the tumour was embedded in paraffin:
5mm sections were stained with haematoxylin and eosin.
Apoptosis was detected by DNA fragmentation using TdT
incorporation of nucleotides on 30 ends of DNA (TUNEL
technique). Briefly, 5mm of glioma C6 tumour sections was
dewaxed and immersed in 3% H2O2 to block endogenous
peroxidase; after washing with distilled water, proteinase K
(20mgml
 1) was applied to the specimens for 15min at room
temperature. Detection of apoptosis in situ was made by ApopTag
Peroxidase (Oncor, Gaithersburg, MD, USA) that detects fragmen-
ted DNA and was performed according to the manufacturer ´s
conditions. Sections were counterstained with methyl-green.
Positive control sections were prepared by nicking DNA with
DNase and negative control sections were prepared by substituting
with distilled water for working strength TdT enzyme. The
proportion of apoptotic cells was expressed as apoptotic rate,
which represented the number of apoptotic cells among 1000
glioma C6 nucleated cells, excluding segmented neutrophils due to
their short lifespan.
Determination of growth factors in vivo
In all, 10 samples from each experimental group were unfrozen,
weighted, and homogenised at 41C (1:1) in saline solution;
70mgml
 1 of phenylmethylsulphonyl fluoride (PMSF) was added
for inhibition of proteases, the lysate was centrifuged at 6500g for
20min and kept at  701C until analysis. Tissue contents of bFGF,
VEGF, PDGF and HGF were measured by enzyme-linked
immunosorbent assay (ELISA) (R&D system, Minneapolis, MN,
USA). Each sample was assayed by duplicate and reported as
means7s.d.
Treatment of C6 cells in culture
We separated C6 glioma cells in four groups: control cells (without
treatment); cultures treated with Ang II (10
 7 M); cultures treated
with Losartan (10
 5 M) (Stroth et al, 2000) and cultures treated
with both Ang II and Losartan (L–A) at the same doses. All
cultures were kept in a serum-free medium at 371C, in humidified
environment with 5% CO2. The culture medium used for cells
incubated for long periods was changed every 24h containing
either Ang II, losartan or Ang ll plus losartan at the mentioned
doses.
Cell viability of C6 glioma in culture
For quantification of cell viability, 6.5 10
5 glioma cells were
cultured in microtitre plates (96 wells) with 100ml culture medium
and incubated for 24h in a humidified atmosphere; 10mlo f
tetrazolium salts (MTT) was added to each well and left for 4h;
these salts were cleaved into a coloured formazan product by
metabolically active cells; afterwards 100ml of solubilisation
solution was added, the plates were allowed to stand overnight
inside the incubator. After checking for complete solubilisation of
the purple formazan crystals, the absorbance was measured at
570nm, the reference wavelength was 650nm. We obtained the
percentage of viable cells from three assays, the control was used as
reference (100%). Two replicates were perfomed using the same
dosages.
Apoptotic rate in vitro by flow cytometry
For quantification of apoptosis by flow cytometry, 10
6 C
6 glioma
cells were trypsinised and transferred to 1.5ml Eppendorf tubes
and cultured with DME culture medium either alone (controls) or
with Losartan 10
 5 M, or with Ang II 10
 7 M, or with the mixture of
losartan/Ang II (LA). Cultured cells were maintained at 371C with
5% CO2 during 6, 12, 24, 48 or 96h. The culture medium of those
experimental groups which needed a long time of incubation was
changed every day. At the end of the incubation period, the cells
were centrifuged at 2000g, the supernatant was discarded. Induced
apoptosis was detected by flow-cytometric analysis of the
permeabilised, propidium-iodide-stained cells (Telford et al,
1992). Samples (10
6cellsml
 1) were washed once in PBS and
the pellets were re-suspended in 80% ethanol at 41C for 60min.
To detect apoptosis by flow cytometry, fixed cells were centrifuged,
re-suspended in 1ml PBS, and kept at 371C for 20min before
staining with a solution of 0.1% Triton X-100, 0.1mM EDTA(Na)2,
5Uml
 1 RNase and 20mgml
 1 propidium iodide in PBS. Samples
were stored in the dark at room temperature and analysed
with a Facscalibur Registered Trademark (Becton Dickinson & Co.,
San Jose, CA, USA). Using the cell quest software (San Jose
CA, USA), cell number (10
4) was detected. Cell percentages in
the different phases of the cell cycle were estimated according
to the Fox’s method (Lacombe et al, 1988). The assays were made
by triplicate.
Apoptotic rate in vitro by ELISA
For quantification of apoptosis by ELISA, 10
5 C
6 glioma cells were
trypsinised and transferred to 1.5ml Eppendorf tubes and cultured
with DME culture medium either alone (controls) or with Losartan
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 5 M, or with Ang II 10
 7 M, or with the mixture of LA. Cultured
cells were maintained at 371C with 5% CO2 during 6, 12, 24, 48 or
96h. The culture medium of those experimental groups
which needed a long time of incubation was changed every day.
At the end of the incubation period, the cells were centrifuged
at 2000g, the supernatant was discarded and the cells were
re-suspended in 1ml of culture medium with 10% DMSO and
kept in liquid nitrogen until processed. At that time, the vials
were warmed at 371C and the cells were washed with culture
medium by centrifugation at 2000g. The cells were then re-
suspended with incubation buffer (Cell Death detection ELISA
Kit, Boehringer Mannheim catalogue: 1544675) at 41C
during 30min. The cellular lysate was centrifuged at 20000g for
10min and 400ml of the supernatant were removed (cytoplasmic
fraction) and diluted 1:10 with incubation buffer, absorbance
was measured at 405nm, the substrate solution was used as
blank. The assays were made by triplicate; 10
6 C6 cells in
hypertonic buffer and 10
6 C6 cells with camptotensin were used
as positive controls.
Statistical analysis
Values were expressed as means7s.d.; for the quantification of
apoptotic rate, the kappa value was used as the interobserver
variability value. Statistical analysis was made using SPSS v10
software. Comparisons between groups were made by ANOVA and
Tukey tests. Statistical significance was set at a P-value of 0.05.
RESULTS
Effect of the blockage of AT1 receptor on tumoral growth
and apoptotic rate in vivo
All animals survived until the end of the experiment. In all
controls, the tumour grew to a very large size (over 6cm diameter);
there was no case of spontaneous involution. When compared to
controls (mean volume: 55710cm
3) a significant decrease in
tumour volume was seen in animals treated with L40 (3077cm
3)
and with L80 (1979cm
3)( Po0.05 and 0.01, respectively). Results
were similar to those from our previous report (Rivera et al, 2001).
The apoptotic rate was higher in the L80 group (84.274.1) than in
controls (2378) or in the L40 group (13.674.3) (Po0.01); no
differences were seen when L40 group was compared with controls
(Figure 1). Comparisons of haematological and chemical blood
parameters measured at the end of the study showed no differences
between groups.
Growth factors in neoplastic tissue
Mean contents of PDGF, bFGF and VEGF were higher in tumours
from control animals (PDGF¼1,1957261, bFGF¼89374, and
VEGF¼15477pgmg
 1 of tissue) than in tumours of animals
treated with L40 (PDGF¼609784, P¼0.05; bFGF¼857712,
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Figure 2 Effect of the blockage of AT1 receptor with losartan on the contents of PDGF, FGF, VEGF and HGF in C6 rat glioma. A significant reduction in
the concentration of PDGF, FGF and VEGF was obtained with losartan treatment.
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Figure 1 Effect of losartan administration at doses of 40 and 80mgKg
 1
on the apoptotic rate in tissue sections of C6 glioma (TUNEL stain). A
significant increase of the apoptosis was observed with losartan treatment
at 80mgKg
 1.
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 1, P¼0.011) and those
treated with L80 (PDGF¼451745, P¼0.018; bFGF¼827714,
P¼0.001; and VEGF¼105719pgmg
 1, P¼0.013). However, no
significant differences were seen on HGF contents between
controls (97720pgmg
 1) and L40-(100729pgmg
 1) or L80-
treated rats (105719pgmg
 1)( P¼0.65) (Figure 2).
Effects of Ang II, losartan and LA on cell cultures
The percentage of viable cells was significantly smaller in cultures
treated with L–A at 6 and 12h as compared with controls (P¼0.01
and 0.05, respectively); however, no differences were seen later, at
24, 48 and 96h. The percentage of viable cells was higher in cells
cultured with Ang II at 48 and 96h as compared to controls
(P¼0.04 for both determinations). Treatment with Losartan had
no effect on cell viability (Figure 3).
Apoptosis rate in vitro by flow cytometry
A significative increase of apoptosis was observed in cells treated
with L–A particularly at 6h as compared to controls (P¼0.05)
and with the losartan group (P¼0.012), and at 12h as compared
with the groups Ang II (P¼0.007) and losartan (P¼0.001), which
was maintained at 24h with losartan (P¼0.007). No differences
were found at 48, 72 and 96h (Figure 4A).
Apoptosis rate in vitro by ELISA
Cells cultured with Ang II showed increased apoptotic rate at 6h
when compared with losartan (P¼0.012) and at 12h when
compared to controls (P¼0.012). When compared with controls,
apoptosis was increased in cells treated with L–A (P¼0.007), with
losartan (P¼0.003) and with Ang II (P¼0.011) at 6h, as well as
the cells treated with L–A at 12h (P¼0.05). No differences were
found at 24, 48, 72 and 96h (Figure 4B).
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viability was observed in the cells treated with Ang II alone.
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sDISCUSSION
Malignant gliomas contain large quantities of VEGF, PDGF, bFGF
and HGF, as well as their receptors (Stefanik et al, 1991;
Westermark et al, 1995; Arrieta et al, 2002; Steiner et al, 2003);
their concentrations are related to vascular density, radioresistance,
cell proliferation, degree of malignancy and patient ´s survival
(Westermark et al, 1995; Gorski et al, 1999). Angiotensin II
stimulates the production of these growth factors (Peng et al, 2001;
Tamarat et al, 2002); this effect can be blocked by AT1 antagonists
but not by AT2 antagonists (Tamarat et al, 2002). Normal and
neoplasic astrocytes including C6 glioma cells express AT1 and AT2
receptors for Ang II (Rivera et al, 2001; Fogarty et al, 2002). We
have previously shown in experimentally induced C6 glioma in rats
that the selective blockage of AT1 receptor reduces cell prolifera-
tion, angiogenesis and tumour growth (Rivera et al, 2001).
However, the participative mechanisms were unclear. In this study,
we found that the blockage of AT1 decreases the synthesis of the
growth factors VEGF, PDGF and bFGF, coincident with the
reduction of tumour size, cell proliferation and vascular density.
The effect of losartan in the synthesis of growth factors is more
intense in PDGF, which is inhibited with the blockage of AT1 in
several experimental models; nonetheless, VEGF and FGF syntheses
are also statistically reduced. However, the reduction of angiogen-
esis previously reported might be a consequence of VEGF and FGF
inhibition due to a blockage of PDGF’s stimuli, this would explain
why the effect is not dose-dependent on losartan. Although HGF is
also overexpressed in malignant gliomas and related to the degree
of malignancy (Arrieta et al, 2002) and Ang II also participates in
its synthesis (Matsumoto et al, 2003), in this study no effect on HGF
contents was observed after blockage of the AT1 receptor.
Additionally, our results in vitro show that the reduction on cell
viability within the firsth of Ang II plus losartan administration
was also associated with the induction of apoptosis but only during
the first 12h, whereas the administration of Ang II alone stimulates
cell proliferation during 24h after exposure. Increase of apoptosis
in glioma C6 in vivo was seen only at high doses of losartan
(80mgKg
 1); this effect was also obtained in cultured C6 cells with
the simultaneous administration of losartan and Ang II; it seems
that the selective blockage of AT1 may lead to disequilibrium of
AT1/AT2 relation that promotes AT2 receptor stimulation which, in
turn, could increase its proapoptotic effects. It is also likely that, in
this condition, the presence of Ang II promotes apoptosis, as this
effect is prevented by deletion of the AT2 receptor gene (Yamada
et al, 1996). Our findings are in agreement with studies in PC12W
cells and neurons from newborn rats, showing that apoptosis is
increased either by the selective stimulation of AT2 receptor or by
the blockage of AT1 receptor simultaneous to the administration of
Ang ll (Stoll et al, 1995; Yamada et al, 1996; Goldenberg et al, 2001;
Suzuki et al, 2002).
Subucutaneous C6 glioma, in contrast to brain glioma, allowed
us to measure tumour growth for a longer time and to determine a
potential therapeutic effect when the drug is administered for long
periods. However, similar results are to be expected in brain
glioma as the blood-brain barrier is interrupted in brain tumours,
facilitating the entrance of drugs into the tumour.
Angiogenesis and apoptosis are primordial features of malignant
tumours, constituting attractive therapeutic targets; drugs that
inhibit angiogenesis or promote apoptosis could be associated
to cytotoxic agents to improve antitumoral therapy. The fact
that multifunctional hormonal systems, such as the renin–
angiotensin–aldosterone system, influence tumour growth and
angiogenesis provides interesting pathways to the study of cancer.
The antineoplastic activity obtained by the selective blockage of
AT1 in malignant glioma seems to be mediated by two different
mechanisms, inhibition of the synthesis of growth factors and
promotion of apoptosis, providing a potential therapeutic adjuvant
for malignant gliomas.
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